TEVA - テバ・ファ―マス―ティカル・インダストリ―ズ ()

TEVAのニュース

   Teva Pharmaceutical Industries Limited 2022 Q4 - Results - Earnings Call Presentation  2023/03/02 18:13:05 Seeking Alpha
The following slide deck was published by Teva Pharmaceutical Industries Limited in conjunction with their 2022 Q4 earnings call.
   Teva prices upsized $2.49B sustainability-linked senior notes offering  2023/03/02 11:15:02 Seeking Alpha
Teva Pharmaceutical Industries (TEVA) has priced upsized offering of approximately $2.49B (from $2.06B) of its sustainability-linked senior notes.The company also increased the…
   Teva to raise $2.06B in sustainability-linked senior notes offering, launches $2.25B in debt tender offers for notes  2023/02/27 10:18:21 Seeking Alpha
Teva Pharmaceutical (TEVA) plans to issue $2.06B of sustainability-linked senior notes under its sustainability-linked financing framework established in October 2021, as updated in…
   Teva to Present New Data from CONNECT2 Study on its Digihaler System at the American Academy of Allergy, Asthma and Immunology (AAAAI) 2023 Annual Meeting  2023/02/24 13:00:00 Wallstreet:Online
Teva Pharmaceuticals USA, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that new data on its Digihaler System will be presented at the American Academy of Allergy, Asthma and Immunology (AAAAI) 2023 Annual Meeting, being held February 24-27 in San Antonio, Texas. The data includes findings from the CONNECT2 clinical trial program as well as
   Teva to Present New Data from CONNECT2 Study on its Digihaler® System at the American Academy of Allergy, Asthma and Immunology (AAAAI) 2023 Annual Meeting  2023/02/24 13:00:00 Teva Pharmaceutical Industries
Real-world insights fueled by Digihaler technology and utility of its data in patients with asthma Digihaler is the first and only smart inhaler system that can provide objective data to help patients and their doctors better support asthma management Teva Pharmaceuticals USA, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that new data on its Digihaler System will be presented at the American Academy of Allergy, Asthma and Immunology (AAAAI) 2023 Annual Meeting, being held February 24-27 in San Antonio, Texas. The data includes findings from the CONNECT2 clinical trial program as well as information on patients and healthcare professionals'' real-world use of the smart inhaler system. The Digihaler System is the first and only smart inhaler system with built-in sensors that provide objective inhaler event data to help patients and their doctors support asthma management and develop personalized treatment plans. The data will be
   Teva to raise $2.06B in sustainability-linked senior notes offering, launches $2.25B in debt tender offers for notes  2023/02/27 10:18:21 Seeking Alpha
Teva Pharmaceutical (TEVA) plans to issue $2.06B of sustainability-linked senior notes under its sustainability-linked financing framework established in October 2021, as updated in…
   Teva to Present New Data from CONNECT2 Study on its Digihaler System at the American Academy of Allergy, Asthma and Immunology (AAAAI) 2023 Annual Meeting  2023/02/24 13:00:00 Wallstreet:Online
Teva Pharmaceuticals USA, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that new data on its Digihaler System will be presented at the American Academy of Allergy, Asthma and Immunology (AAAAI) 2023 Annual Meeting, being held February 24-27 in San Antonio, Texas. The data includes findings from the CONNECT2 clinical trial program as well as
   Teva to Present New Data from CONNECT2 Study on its Digihaler® System at the American Academy of Allergy, Asthma and Immunology (AAAAI) 2023 Annual Meeting  2023/02/24 13:00:00 Teva Pharmaceutical Industries
Real-world insights fueled by Digihaler technology and utility of its data in patients with asthma Digihaler is the first and only smart inhaler system that can provide objective data to help patients and their doctors better support asthma management Teva Pharmaceuticals USA, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that new data on its Digihaler System will be presented at the American Academy of Allergy, Asthma and Immunology (AAAAI) 2023 Annual Meeting, being held February 24-27 in San Antonio, Texas. The data includes findings from the CONNECT2 clinical trial program as well as information on patients and healthcare professionals'' real-world use of the smart inhaler system. The Digihaler System is the first and only smart inhaler system with built-in sensors that provide objective inhaler event data to help patients and their doctors support asthma management and develop personalized treatment plans. The data will be
   Teva Pharma Reports Publication of New Clinician Scale to Assess the Impact of Tardive Dyskinesia on Patients Lives  2023/02/23 13:09:01 Investing.com
https://www.investing.com/news/assorted/teva-pharma-reports-publication-of-new-clinician-scale-to-assess-the-impact-of-tardive-dyskinesia-on-patients-lives-432SI-3012247
   Teva Announces Publication of New Clinician Scale in Journal of Clinical Psychiatry to Assess the Impact of Tardive Dyskinesia on Patients’ Lives  2023/02/23 13:00:00 Teva Pharmaceutical Industries
First-of-its-kind scale provides a standardized method for healthcare providers to measure tardive dyskinesia (TD) burden beyond movement severity Developed in partnership with the TD community, this scale incorporates insights from patients, caregivers and providers Offers the potential to more accurately monitor disease progression and help improve overall TD treatment and care Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the print publication of the IMPACT-TD Scale, an easy-to-use, standardized and clinician-rated assessment. The scale, developed by a consensus panel, will assist healthcare providers in determining the impact of tardive dyskinesia (TD) on different aspects of a patient’s daily functioning. IMPACT-TD categorizes the consequences of TD symptoms into multiple functional domains: social, psychological/psychiatric, physical and vocational/educational/recreational. The scale was developed to collect
   Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market to Witness Huge Growth by Key Players: Novartis, Pfizer, Fresenius Kabi, Teva Pharmaceuticals, Sun Pharma  2022/11/30 08:22:34 OpenPR
ReportsnReports publishes the report titled Gastroenteropancreatic Neuroendocrine Tumor Therapeutics that presents a 360-degree overview of the market under one roof. The report is developed with the meticulous efforts of an enthusiastic and experienced team of experts, analyts, and researchers that
   Marksans Pharma Limited Q2 FY23 Earnings Conference Call Insights | AlphaStreet  2022/11/25 14:19:03 AlphaStreet
Key highlights from Marksans Pharma Limited (MARKSANS) Q2 FY23 Earnings Concall Q&A Highlights: [00:12:45] Madhav Shastri asked about the new acquisition made of Teva Pharma, and the expected capex on the facility. Mark Saldanha MD clarified that the amount the company plans to spend including the acquisition cost and capex is INR200 crore. [00:13:36] Madhav
   Teva Pharma PT Lowered to $7 at Piper Sandler  2022/11/23 12:37:09 Investing.com
https://www.investing.com/news/pro/teva-pharma-pt-lowered-to-7-at-piper-sandler-432SI-2950779
   AbbVie Finalizes To Pay Around $2.4B In Settlement Against US Opioid Lawsuits  2022/11/22 20:01:42 Benzinga
Teva Pharmaceutical Industries Ltd (NYSE: TEVA ) and AbbVie Inc (NYSE: ABBV ) have finalized the settlement''s terms worth over $6.6 billion to resolve several lawsuits by U.S. state and local governments over the marketing of opioid painkillers. Under the deals, first announced in July, Teva will pay up to $4.25 billion, including a supply of the overdose drug naloxone. AbbVie will pay up to $2.37 billion. Reuters reported that … Full story available on Benzinga.com
   CORRECTED (OFFICIAL) -FOCUS-Generic drugmakers Teva and Sandoz make major push to biosimilars  2022/11/22 19:40:56 National Post
Generic drug makers Teva Pharmaceutical Industries and Sandoz say they are planning a significant ramp-up in production of biosimilars – copies of high-priced drugs used to treat illnesses such as rheumatoid arthritis and cancer – aiming to increase their share of an expanding market. More than 55 brand-name blockbuster biologic drugs, each with peak annual […]

calendar